Carlyle and SK Capital Acquire bluebird bio
May 14, 2025
bluebird bio entered into a definitive agreement to be acquired by funds managed by Carlyle and SK Capital Partners, with expected close in the first half of 2025. Under the deal, bluebird stockholders are set to receive $3.00 per share in cash plus a contingent value right (CVR) of up to $6.84 per share if a net sales milestone is achieved by 2027 (or an alternative $5.00 per share cash option later added).
- Buyers
- Carlyle, SK Capital Partners, LP, Beacon Parent Holdings, L.P., Beacon Merger Sub, Inc.
- Targets
- bluebird bio, Inc.
- Industry
- Healthcare Services
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.